Cargando…
Generation of Orthotopic Patient-Derived Xenografts in Humanized Mice for Evaluation of Emerging Targeted Therapies and Immunotherapy Combinations for Melanoma
SIMPLE SUMMARY: Patient-derived xenografts (PDX) are valuable models in preclinical oncology drug development. However, they are not well suited for testing immune-based therapies. In contrast, when humanized mice are developed by xenotransplantation of irradiated mice with human CD34+ stem cells to...
Autores principales: | Yan, Chi, Nebhan, Caroline A., Saleh, Nabil, Shattuck-Brandt, Rebecca, Chen, Sheau-Chiann, Ayers, Gregory D., Weiss, Vivian, Richmond, Ann, Vilgelm, Anna E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377652/ https://www.ncbi.nlm.nih.gov/pubmed/37509357 http://dx.doi.org/10.3390/cancers15143695 |
Ejemplares similares
-
Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade
por: Yan, Chi, et al.
Publicado: (2021) -
Proximity of immune and tumor cells underlies response to BRAF/MEK-targeted therapies in metastatic melanoma patients
por: Yan, Chi, et al.
Publicado: (2022) -
Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer
por: Yan, Chi, et al.
Publicado: (2021) -
Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy
por: Vilgelm, Anna E., et al.
Publicado: (2019) -
MDM2 Antagonists Counteract Drug-Induced DNA Damage
por: Vilgelm, Anna E., et al.
Publicado: (2017)